Custom Report

La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis and assessment reports can be prepared according to the specifications of the client from the pharmaceutical or biotechnology industry.

More info

Genmab A/S (CSE: GEN) announced today that Genmab initiates research cooperation with the Danish Head and Neck Cancer Group (DAHANCA).

Copenhagen, Denmark | Mar 16, 2007 | Genmab A/S (CSE: GEN) announced today that Genmab initiates research cooperation with the Danish Head and Neck Cancer Group (DAHANCA). Under the cooperation Genmab will supply the fully human antibody HuMax-EGFr™ (zalutumumab) to a Phase III front line study of approximately 600 Head and Neck cancer patients run by the DAHANCA-group. The study will be financed by the DAHANCA-group, who is also responsible for negotiating the study protocol with authorities. Following finalization of the study protocol the DAHANCA-group will be responsible for running the study and subsequent publication of results. Genmab has all the rights to regulatory use of both safety and efficacy data from the study. Further details of the study are under negotiations by the DAHANCA-group.

SOURCE: Genmab A/S

Post Views: 111